Drug Profile


Alternative Names: UP 2691

Latest Information Update: 21 Nov 2007

Price : $50

At a glance

  • Originator UPSA
  • Class Analgesics; Anxiolytics; Small molecules
  • Mechanism of Action Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Pain

Most Recent Events

  • 10 Feb 1999 UP 2691 is now called ruzadolane
  • 14 Oct 1998 No-Development-Reported for Anxiety disorders in France (Unknown route)
  • 04 Aug 1998 A study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top